Terms: = Breast cancer AND B2M, P61769, 567, ENSG00000166710 AND Treatment
52 results:
1. [Upregulation of MHC I Antigen Processing Machinery Gene Expression in breast cancer Cells by Trichostatin A].
Murtadha AH; Sharudin NA; Azahar IIM; Che Has AT; Mokhtar NF
Mol Biol (Mosk); 2023; 57(6):21-30. PubMed ID: 38062971
[TBL] [Abstract] [Full Text] [Related]
2. treatment times for delivering adjuvant breast radiotherapy at a cancer centre in Ontario, Canada.
Chan S; MacKenzie S; Bosnic S; Wong G; Zhang L; Finkelstein S; Lam E; Russell S; Gallant F; Wronski M; Leung E; Chow E; Chin L
J Med Imaging Radiat Sci; 2023 Dec; 54(4):611-619. PubMed ID: 37718151
[TBL] [Abstract] [Full Text] [Related]
3. Impact of travel burden on the treatment of stage I and II breast cancer: A National cancer Database analysis.
Perry NJ; Sharon CE; Tortorello GN; Ma KL; Straker RJ; Fayanju OM; Tchou JC; Miura JT; Karakousis GC
Surgery; 2023 Oct; 174(4):794-800. PubMed ID: 37562985
[TBL] [Abstract] [Full Text] [Related]
4. Genetically engineered neural stem cells expressing cytosine deaminase and interferon-beta enhanced T cell-mediated antitumor immunity against gastric cancer in a humanized mouse model.
Choi Y; Lee HK; Ahn D; Nam MW; Go RE; Choi KC
Life Sci; 2023 Sep; 328():121866. PubMed ID: 37331506
[TBL] [Abstract] [Full Text] [Related]
5. Radiomics model of diffusion-weighted whole-body imaging with background signal suppression (DWIBS) for predicting axillary lymph node status in breast cancer.
Haraguchi T; Kobayashi Y; Hirahara D; Kobayashi T; Takaya E; Nagai MT; Tomita H; Okamoto J; Kanemaki Y; Tsugawa K
J Xray Sci Technol; 2023; 31(3):627-640. PubMed ID: 37038802
[TBL] [Abstract] [Full Text] [Related]
6. Construction of an lncRNA model for prognostic prediction of bladder cancer.
Shi C; Li Y; Wan E; Zhang E; Sun L
BMC Med Genomics; 2022 Dec; 15(1):257. PubMed ID: 36514150
[TBL] [Abstract] [Full Text] [Related]
7. Volume matters: breast induration is associated with irradiated breast volume in the Danish breast cancer Group phase III randomized Partial breast Irradiation trial.
Thomsen MS; Alsner J; Nielsen HM; Jakobsen EH; Nielsen MH; Møller M; Pedersen AN; Yates E; Berg M; Lorenzen E; Jensen I; Josipovic M; Overgaard J; Offersen BV;
Radiother Oncol; 2022 Dec; 177():231-235. PubMed ID: 36265685
[TBL] [Abstract] [Full Text] [Related]
8. Survival comparison between postoperative and preoperative radiotherapy for stage I-III non-inflammatory breast cancer.
Zhang Y; Xu Z; Chen H; Sun X; Zhang Z
Sci Rep; 2022 Aug; 12(1):14288. PubMed ID: 35995985
[TBL] [Abstract] [Full Text] [Related]
9. Prognostic Impact of Radiation Therapy in Pure Mucinous breast Carcinoma.
Chevli N; Wang K; Haque W; Schwartz MR; Nangia J; Sasaki J; Farach AM; Hatch SS; Butler EB; Teh BS
Clin Breast Cancer; 2022 Oct; 22(7):e807-e817. PubMed ID: 35915020
[TBL] [Abstract] [Full Text] [Related]
10. Real-World Effectiveness of Denosumab and Bisphosphonates on Risk of Vertebral Fractures in Women with breast cancer Undergoing treatment with Aromatase Inhibitors.
Mazziotti G; Pedersini R; Vena W; Cosentini D; Carrone F; Pigni S; Simoncini EL; Torrisi R; Zambelli A; Farina D; Balzarini L; Lania AG; Berruti A
Calcif Tissue Int; 2022 Nov; 111(5):466-474. PubMed ID: 35902384
[TBL] [Abstract] [Full Text] [Related]
11. A real-world retrospective study of the use of Ki-67 testing and treatment patterns in patients with HR+, HER2- early breast cancer in the United States.
Brown J; Scardo S; Method M; Schlauch D; Misch A; Picard S; Hamilton E; Jones S; Burris H; Spigel D
BMC Cancer; 2022 May; 22(1):502. PubMed ID: 35524219
[TBL] [Abstract] [Full Text] [Related]
12. Comparison of clinical features and the impact of reproductive factors on by age at diagnosis young and elderly breast cancer patients in the middle Anatolian region of Turkey.
Eren SK; Arslan A; Çalışkan EÇ; Akay E; Özhan N; Topuz Ö; Ertan T
Eur Rev Med Pharmacol Sci; 2022 Apr; 26(7):2227-2237. PubMed ID: 35442507
[TBL] [Abstract] [Full Text] [Related]
13. [Impact and clinical value of the revised 2019 Chinese HER-2 testing guidelines on the detect result evaluation of invasive breast cancer cases with equivocal HER-2 immunostaining by using fluorescence in situ hybridization].
Zhang L; Wang WW; Jiang GZ; Zhang YP
Zhonghua Zhong Liu Za Zhi; 2021 Aug; 43(8):833-837. PubMed ID: 34407587
[No Abstract] [Full Text] [Related]
14. Obesity and high neutrophil-to-lymphocyte ratio are prognostic factors in non-metastatic breast cancer patients.
Orlandini LF; Pimentel FF; Andrade JM; Reis FJCD; Mattos-Arruda L; Tiezzi DG
Braz J Med Biol Res; 2021; 54(10):e11409. PubMed ID: 34406210
[TBL] [Abstract] [Full Text] [Related]
15. A Comprehensive Molecular Analysis of in Vivo Isolated EpCAM-Positive Circulating Tumor Cells in breast cancer.
Strati A; Zavridou M; Kallergi G; Politaki E; Kuske A; Gorges TM; Riethdorf S; Joosse SA; Koch C; Bohnen AL; Mueller V; Koutsodontis G; Kontopodis E; Poulakaki N; Psyrri A; Mavroudis D; Georgoulias V; Pantel K; Lianidou ES
Clin Chem; 2021 Oct; 67(10):1395-1405. PubMed ID: 34322698
[TBL] [Abstract] [Full Text] [Related]
16. breast cancer in Brazil: Screening program and surgical approach.
Nascimento JHF; Vieira ATS; Souza Filho BM; Tomaz SC; Delgado Bocanegra RE; Melo Costa VS; Johnson LFP; Gusmão-Cunha A; Silva Neto MM; Andrade AB
Cancer Epidemiol; 2021 Aug; 73():101970. PubMed ID: 34216956
[TBL] [Abstract] [Full Text] [Related]
17. Comparison of survival in non-metastatic inflammatory and other T4 breast cancers: a SEER population-based analysis.
Jiao D; Zhang J; Zhu J; Guo X; Yang Y; Xiao H; Liu Z
BMC Cancer; 2021 Feb; 21(1):138. PubMed ID: 33549037
[TBL] [Abstract] [Full Text] [Related]
18. Implementation of an integrated framework for a breast cancer screening and navigation program for women from underresourced communities.
Henderson V; Tossas-Milligan K; Martinez E; Williams B; Torres P; Mannan N; Green L; Thompson B; Winn R; Watson KS
Cancer; 2020 May; 126 Suppl 10():2481-2493. PubMed ID: 32348565
[TBL] [Abstract] [Full Text] [Related]
19. A 3-gene biomarker signature to predict response to taxane-based neoadjuvant chemotherapy in breast cancer.
Kallarackal J; Burger F; Bianco S; Romualdi A; Schad M
PLoS One; 2020; 15(3):e0230313. PubMed ID: 32196521
[TBL] [Abstract] [Full Text] [Related]
20. Exosome-transmitted miR-567 reverses trastuzumab resistance by inhibiting ATG5 in breast cancer.
Han M; Hu J; Lu P; Cao H; Yu C; Li X; Qian X; Yang X; Yang Y; Han N; Dou D; Zhang F; Ye M; Yang C; Gu Y; Dong H
Cell Death Dis; 2020 Jan; 11(1):43. PubMed ID: 31969559
[TBL] [Abstract] [Full Text] [Related]
[Next]
